Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily living among adults who tested negative for antibodies targeting the acetylcholine receptor (AChR) — the most common cause of the disease. That’s according to top-line data from an ongoing Phase 3…
Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune response — might help keep myasthenia gravis (MG) under control. That’s according to the findings of a new study from China using immune cells from patients, which suggested that…
A case report from Germany showed that two women with severe, treatment-resistant myasthenia gravis (MG) responded well to blinatumomab, suggesting the anti-cancer medication may offer a new option for hard-to-treat autoimmune diseases. “Since this first-in-human experience comprises two cases, our findings should be viewed as proof-of-concept rather than evidence…
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age alone increased the risk of death, using azathioprine for many years was linked to serious blood problems and cases of cancer, a study has found. However, “although the use of…
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels of disease-causing antibodies in the bloodstream. Researchers also observed that povetacicept outperformed efgartigimod — approved as Vyvgart…
Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate for the treatment of myasthenia gravis (MG) and other autoimmune diseases driven by self-reactive antibodies — outside of China, Hong Kong, Macau, and Taiwan. Telitacicept has been approved…
Plasma exchange — a procedure that clears antibodies, such as those that cause myasthenia gravis (MG), from the blood — may be a better myasthenic crisis treatment when used in combination with a procedure used to remove white blood cells, a study found. The combined procedure, called lymphoplasmapheresis, achieved…
Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment Seismic Therapeutic designed to break down harmful self-reactive antibodies in autoimmune diseases like myasthenia gravis (MG). Running at a single site in Australia, the Phase 1 clinical…
Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in about four in every five children with juvenile MG, with few side effects. That’s according to a meta-analysis of nine studies from China and Japan, which also found tacrolimus…
People with more severe myasthenia gravis (MG) have a greater likelihood of experiencing episodes of exacerbation, when symptoms worsen or reappear, and may need more medical care, according to the findings of a new study. The study also suggested that personalized treatment for these MG patients may ease the…
Get regular updates to your inbox.
